Expertise in
1
conditions

Enrico N. De Toni

Munich, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Enrico De Toni practices in Munich, Germany. Mr. De Toni is highly rated in 1 condition, according to our data. His top areas of expertise are Liver Cancer, Cirrhosis, Cerebral Hypoxia, Liver Transplant, and Colonoscopy.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Munich, BY 81377, Germany
Other Locations
Erlangen, BY, Germany
Maximilian, BY, Germany
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Recruiting
Publish Date: June 14, 2024
Intervention Type: Combination product
Study Drug: Atezolizumab Injection, Bevacizumab Injection
Study Phase: Phase 2

121 Total Publications

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.
Journal: Cancers
Published: February 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Toni's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile